TickerTalks
Browse all tickers →
TickerTalks›$PRME
PRPRME

Prime Medicine, Inc.

$PRME·$583M·Biotechnology·Healthcare
$3.13-3.2%YTD-7.4%1Y+50.0%
Mentions · last 7 days
2026-06-17: 168 posts2026-06-18: 140 posts2026-06-19: 20 posts2026-06-20: 7 posts2026-06-21: 5 posts2026-06-22: 56 posts2026-06-23: 22 posts432-1%
Price updated 8m ago·X counts updated 21h ago
PRPRME
$PRMEPrime Medicine, Inc.
$3.14-3.24%432 posts-1%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PRME, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-06-24

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Gene-editing platform with two FDA/Medsafe wins this week — small-cap biotech inflection forming.

Prime Medicine is a clinical-stage gene-editing company developing prime-editing therapies — a category beyond CRISPR/Cas9 that promises precise edits without double-strand breaks — and the live moment is two regulatory wins in a single week reframing the equity from speculation to clinical-platform reality.

  • The regulatory progress is the unambiguous bull catalyst: FDA granted RMAT (Regenerative Medicine Advanced Therapy) designation to PM359 for chronic granulomatous disease on June 22 (on the strength of Phase 1/2 data published in NEJM), and New Zealand's Medsafe cleared the CTA for PM577a — the first-ever clinical authorization for an in vivo prime-editing therapy, targeting Wilson Disease — that's the prime-editing platform finally getting into pivotal-trial settings.
  • The income statement is still pre-meaningful-revenue: Q1 revenue at $0.9M (essentially zero) at -117% gross margin and -5,917% operating margin (FCF -$43M), with FY26 consensus of just $10M revenue and a -$1.00 loss — at 137x trailing sales the equity is anchored on platform optionality, not income; cash runway through next pivotal catalyst is what matters.
  • The sell-side and chart picture is constructive but small: Citizens initiated at Market Outperform with a $6 PT (85% above current), TD Cowen at Buy, the broader gene-editing sector is catching a bid alongside NTLA and BEAM, and at the 25th percentile of the 52-week range there's room for a real re-rate if the next data set lands clean — director awards at $3.06 on June 8 (multiple insiders, ~$1.4M total) are the inside conviction tell.

The August 6 Q2 earnings (and the broader Phase 1/2/3 catalyst calendar through FY27) is the structural window — additional CGD efficacy data plus Wilson Disease enrollment progress turns coiling into a real re-rate; any clinical setback, and the platform-optionality multiple compresses fast. Biotech-binary at this scale, sized accordingly.

Agrees with X sentimentThe bullish 'inflection moment' framing on PM359 RMAT and PM577a Medsafe clearance, plus Citizens $6 PT and TD Cowen Buy, lines up with the filings. The 'frustration the stock hasn't moved more' camp is right that the chart hasn't yet repriced the regulatory wins — they will if the next data set confirms the platform.

What to watch: August 6 Q2 earnings AND additional PM359 / PM577a clinical milestones through FY26-FY27 — needs CGD efficacy data progress and Wilson Disease enrollment. Any clinical setback, and the platform-optionality multiple compresses fast; biotech-binary risk.

On the calendar: 2026-08-06 — Q2 earnings

clinical inflection windowbiotech binaryplatform optionality

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment29 posts analyzed · as of 2026-06-23

Prime Medicine is having a banner week, with the FDA granting RMAT designation to PM359 for chronic granulomatous disease on the strength of Phase 1/2 data published in NEJM, and New Zealand's Medsafe clearing the CTA for PM577a, the first-ever clinical authorization for an in vivo prime-editing therapy targeting Wilson Disease. Citizens initiated at Market Outperform ($6 PT) and TD Cowen at Buy, and the broader gene-editing sector is catching a bid alongside NTLA and BEAM. Bulls call this an inflection moment and argue the platform is structurally unique, though some longtime holders vent frustration that the stock hasn't moved more.

Read the AI verdict + X sentiment for $PRME

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops prime editing gene therapies enabling precise genomic insertions and corrections for inherited diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PRME.

Biotechnology · Healthcare

GLP-1 pipeline competition is the dominant structural driver — the ADA conference crystallized oral formulations, dual agonists, and differentiated mechanisms competing for a potential $150B obesity market by 2030. QURE's FDA accelerated approval for AMT-130 (Huntington's disease) this week confirms gene therapy regulatory momentum is still flowing capital to non-GLP-1 precision medicine.

What this means for $PRME

Direct beneficiary — Prime Medicine's prime editing gene therapies enabling precise genomic insertions directly benefit from the gene therapy regulatory momentum demonstrated by QURE's FDA accelerated approval.

Top industry ETF

$IBBiShares Biotechnology ETF
+5.0%YTD
+42.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-77.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-51.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-28.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
137.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-189%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-10.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
1.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.28$-0.24-16.7%
Q4 2025Mar 3, 2026$-0.22$-0.25+12.0%
Q3 2025Nov 7, 2025$-0.32$-0.28-14.3%
Q2 2025Aug 7, 2025$-0.41$-0.36-13.9%
Next earningsThu, Aug 6·consensus EPS $-0.24

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$856K-41.1%-117%-5918%$-0.28$-42.9M
Q4 FY25$838K-61.6%100%-5800%$-0.26$-37.5M
Q3 FY25$1.2M+486.1%-3491%-4406%$-0.32$-35.3M
Q2 FY25$1.1M—-67.2%-4787%$-0.41$-43.0M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$12.8M$857K – $49.8M-$1.00-$1.20 – -$0.9110
FY27$22.5M$3.8M – $56.2M-$0.91-$1.16 – -$0.698
FY28$31.3M$3.5M – $104.8M-$0.81-$1.10 – -$0.5510
FY29$18.4M$2.1M – $61.4M-$0.93-$3.78 – $0.145
FY30$60.1M$6.7M – $201.1M-$0.82-$3.33 – $0.135

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.25%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-1.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-18.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 59.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today5.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.315-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 11 other (11 awards) in window

See when $PRME insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary

Prime Medicine, Inc. held its 2026 Annual Meeting on June 5, 2026, with 140.4 million of 180.6 million eligible shares represented (77.7%). Stockholders voted to elect Michael Kelly and David Schenkein, M.D. as Class I directors for terms through 2029, and to ratify PricewaterhouseCoopers LLP as auditor for fiscal 2026. Routine governance — no contested proposals.

3New insider — initial holdingsApr 173
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for PRME on 2026-04-17, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KOfficer or director changeApr 168-K — Item 5.02: Officer or director change
AI summary

PRME disclosed a personnel change (8-K Item 5.02, dated 2026-04-16). An executive departure and a new appointment are both reported. Svetlana Makhni as the Chief Financial. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KPress release / Reg FDMar 38-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KPress release / Reg FDJan 128-K — Item 7.01: Press release / Reg FD
+ 11 other (2 proxys · 1 10-Q · 1 earnings 8-K · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)globenewswire.com·2d agoPrime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Diseaseglobenewswire.com·6d agoOcular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?fool.com·9d agoPrime Medicine's Prime Editing Is Worth The Riskseekingalpha.com·12d agoPrime Drink Group Announces Private Placement and Agreed Resolution with Creditorsglobenewswire.com·12d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPRAI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$QURE$DFTX$ALLO$HUMA$ALT$IBRX$APGE
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport